BTL, a global leader in medical technology, is proud to introduce EXOMIND™ in Malaysia—a groundbreaking procedure designed to help patients improve their mental well-being. The treatment is now available at ten clinics across the country, marking the arrival of this pioneering approach to holistic healthcare in Malaysia.

Mental Wellness: A Growing Concern

In Malaysia, depression rates have doubled since 2019, with 1 in 3 Malaysians now facing mental health issues.^1 Globally, mental wellness is the number one health concern among adults, surpassing cancer and obesity.^2 Furthermore, 50% of aesthetic patients were found to struggle with mental wellness.^3

Despite its growing importance, traditional aesthetic and wellness treatments have focused primarily on physical appearance, leaving a critical gap in psychological well-being.

“One of the biggest gaps we see in clinical practice today is the lack of effective support for chronic stress and poor sleep quality, two factors that significantly impact overall health, yet are often under-addressed.

EXOMIND helps bridge this gap by supporting the underlying neurocircuitry involved in stress regulation, emotional balance, and cognitive function. Many patients still fall into a gap where they are struggling but may not require, or may not want, pharmacological treatment, and this is where EXOMIND becomes highly relevant.

It allows us to support patients in a way that is gentle, effective, and aligned with a more holistic approach to health.”

— Dr. Nurul Ain Abdullah, Alainn Clinic

Addressing the Missing Piece in Mental Wellness

EXOMIND’s non-invasive technology comfortably stimulates key areas of the brain responsible for:

• Emotional regulation
• Cognitive function
• Self-control

By activating neural pathways, EXOMIND helps restore healthy brain activity and enhances neural connectivity, leading to improved mental wellness.

EXOMIND integrates advanced ExoTMS™ Technology, representing the latest evolution in non-invasive electromagnetic neuronal stimulation.

This innovation builds upon the well-established foundation of Transcranial Magnetic Stimulation (TMS)—a clinically proven method for enhancing brain function and addressing mental health challenges. ExoTMS further advances this proven technology with state-of-the-art innovations designed to optimize both patient comfort and therapeutic outcomes.

Registered Medical Device in Malaysia

EXOMIND is registered under the Medical Device Act (MDA) Malaysia for the treatment of:

• Depression and anxiety
• Obsessive-compulsive behaviours
• Binge eating

Clinical Results

Clinical research on EXOMIND suggests significant benefits in mental well-being and self-regulation:

• 88% of patients reported improvements in mental well-being.
• 78% felt less stressed.
• 77% experienced improved mood and energy.
• 75% gained better self-control over food cravings.
• Patients seeking weight loss lost an average of 2.3 kg one month after completing treatment by reducing food-craving symptoms—without any physical body intervention.

Full clinical data is available in the accompanying fact sheets covering:

• Mental Wellness
• Sleep & Stress
• Food Cravings
• Binge Eating

A Comfortable & Efficient Experience

With its pioneering approach, EXOMIND sets a new benchmark in holistic care. By complementing existing wellness and aesthetic treatments, it helps patients achieve greater confidence, emotional balance, and self-regulation.

Designed for convenience, EXOMIND offers:

• Treatment sessions in under 30 minutes
• Patient comfort as a priority
• Non-invasive “walk-in, walk-out” procedure
• Drug-free treatment

For more information about EXOMIND and its revolutionary technology, visit: www.btlexomind.com

Now Available at Ten Clinics Across Malaysia

EXOMIND is now offered at ten clinics nationwide, bringing this innovative treatment to patients across major cities in Malaysia.

References

1. National Health and Morbidity Survey (Malaysia)
2. Ipsos Global Health Service Monitor, 2023
3. European Psychiatry, 2021. DOI: 10.1192/j.eurpsy.2021.1224